A randomised phase 2 study of paclitaxel with or without GSK1120212 in advanced wt BRAF melanoma
Read time: 1 mins
Last updated:28th Nov 2011
Phase 1 - To establish the maximum tolerated dose of GSK1120212 in combination with paclitaxel in the treatment of patients with advanced melanoma. Phase 2 - To compare the efficacy of GSK1120212 in combination with paclitaxel, compared with paclitaxel alone in the treatment of patients with advanced or metastatic melanoma.
|Study start date||2011-11-28|